Metabolomic Analysis Identifies Altered Amino Acid Metabolism in HBeAg-positive Chronic Hepatitis B Patients

Chronic hepatitis B virus (HBV) infection poses a substantial public health burden worldwide. Although pegylated-interferon α (PEG-IFNα) and nucleos(t)ide analogues (NAs) are available for treating chronic hepatitis B (CHB), achieving HBeAg seroconversion is still not guaranteed. Moreover, indicators to identify responders and predict the likelihood of HBeAg seroconversion are lacking in the management of HBeAg-positive CHB. Our study is the first metabolomic analysis focusing on the metabolic characteristics of patients with HBeAg-positive CHB undergoing long-term antiviral therapy.慢性乙型肝炎病毒（HBV）感染在全球范围内造成了沉重的公共健康负担。尽管目前已有聚乙二醇干扰素α（PEG-IFNα）与核苷（酸）类似物（NAs）用于慢性乙型肝炎（CHB）的治疗，但仍无法确保实现乙型肝炎e抗原（HBeAg）血清学转换。此外，在HBeAg阳性慢性乙型肝炎患者的临床管理中，尚缺乏用于甄别应答者以及预测HBeAg血清学转换概率的相关指标。本研究是首个聚焦于接受长期抗病毒治疗的HBeAg阳性慢性乙型肝炎患者代谢特征的代谢组学分析。